EpiDestiny, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2016-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.epidestiny.com
Clinical Trials
5
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (100.0%)A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT07006025
- Locations
- 🇺🇸
Montefiore Einstein Medical Center, Bronx, New York, United States
To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05816356
- Locations
- 🇺🇸
Worldwide Clinical Trails Early Phase Services, San Antonio, Texas, United States
Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04086238
- Locations
- 🇺🇸
Worldwide Clinical Trial, San Antonio, Texas, United States
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04055818
- Locations
- 🇺🇸
University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States
Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03828084
- Locations
- 🇺🇸
Worldwide Clinical Trial, San Antonio, Texas, United States
News
No news found